Precigen (NASDAQ:PGEN) Stock Crosses Below Two Hundred Day Moving Average of $2.30

Precigen, Inc. (NASDAQ:PGENGet Rating) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.30 and traded as low as $1.23. Precigen shares last traded at $1.35, with a volume of 2,668,070 shares changing hands.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Precigen in a report on Monday, May 16th.

The company has a debt-to-equity ratio of 2.72, a quick ratio of 5.55 and a current ratio of 6.05. The company has a market cap of $280.39 million, a price-to-earnings ratio of -2.81 and a beta of 2.43. The company has a fifty day moving average of $1.40 and a two-hundred day moving average of $2.30.

Precigen (NASDAQ:PGENGet Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm had revenue of $32.02 million for the quarter, compared to the consensus estimate of $20.90 million. Precigen had a negative return on equity of 79.87% and a negative net margin of 84.48%. Equities analysts expect that Precigen, Inc. will post -0.36 EPS for the current fiscal year.

In other Precigen news, CEO Helen Sabzevari sold 177,968 shares of the stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $1.19, for a total transaction of $211,781.92. Following the completion of the sale, the chief executive officer now owns 897,091 shares of the company’s stock, valued at approximately $1,067,538.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 213,661 shares of company stock worth $257,469 over the last quarter. 42.70% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Cresset Asset Management LLC acquired a new stake in shares of Precigen during the 1st quarter worth approximately $25,000. Inspire Advisors LLC acquired a new stake in shares of Precigen during the 1st quarter worth approximately $35,000. Inspire Investing LLC acquired a new stake in shares of Precigen during the 1st quarter worth approximately $35,000. PFG Advisors acquired a new stake in shares of Precigen during the 4th quarter worth approximately $37,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Precigen during the 4th quarter worth approximately $42,000. 78.16% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile (NASDAQ:PGEN)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.